These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17560603)

  • 1. Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient.
    Klein FA; Pastore A; Masino L; Zeder-Lutz G; Nierengarten H; Oulad-Abdelghani M; Altschuh D; Mandel JL; Trottier Y
    J Mol Biol; 2007 Aug; 371(1):235-44. PubMed ID: 17560603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-like fibril formation by polyQ proteins: a critical balance between the polyQ length and the constraints imposed by the host protein.
    Scarafone N; Pain C; Fratamico A; Gaspard G; Yilmaz N; Filée P; Galleni M; Matagne A; Dumoulin M
    PLoS One; 2012; 7(3):e31253. PubMed ID: 22438863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay between PolyQ and protein context delays aggregation by forming a reservoir of protofibrils.
    Bulone D; Masino L; Thomas DJ; San Biagio PL; Pastore A
    PLoS One; 2006 Dec; 1(1):e111. PubMed ID: 17205115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
    Wetzel R
    Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.
    Adegbuyiro A; Sedighi F; Pilkington AW; Groover S; Legleiter J
    Biochemistry; 2017 Mar; 56(9):1199-1217. PubMed ID: 28170216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.
    Okamoto Y; Nagai Y; Fujikake N; Akiko Popiel H; Yoshioka T; Toda T; Inui T
    Biochem Biophys Res Commun; 2009 Jan; 378(3):634-9. PubMed ID: 19061859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence Context Influences the Structure and Aggregation Behavior of a PolyQ Tract.
    Eftekharzadeh B; Piai A; Chiesa G; Mungianu D; García J; Pierattelli R; Felli IC; Salvatella X
    Biophys J; 2016 Jun; 110(11):2361-2366. PubMed ID: 27276254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards the treatment of polyglutamine diseases: the modulatory role of protein context.
    Robertson AL; Bottomley SP
    Curr Med Chem; 2010; 17(27):3058-68. PubMed ID: 20629626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics analysis of the aggregation propensity of polyglutamine segments.
    Wen J; Scoles DR; Facelli JC
    PLoS One; 2017; 12(5):e0178333. PubMed ID: 28542401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The length dependence of the polyQ-mediated protein aggregation.
    Barton S; Jacak R; Khare SD; Ding F; Dokholyan NV
    J Biol Chem; 2007 Aug; 282(35):25487-92. PubMed ID: 17591778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains.
    Robertson AL; Bate MA; Buckle AM; Bottomley SP
    J Mol Biol; 2011 Nov; 413(4):879-87. PubMed ID: 21945530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamine and neurodegeneration: structural aspects.
    Masino L
    Protein Pept Lett; 2004 Jun; 11(3):239-48. PubMed ID: 15182225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic polyglutamine expansion length correlates with polarity of the flanking sequences.
    Kim M
    Mol Neurodegener; 2014 Nov; 9():45. PubMed ID: 25377768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
    Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
    Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The features of polyglutamine regions depend on their evolutionary stability.
    Mier P; Andrade-Navarro MA
    BMC Evol Biol; 2020 May; 20(1):59. PubMed ID: 32448113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyglutamine Solution-State Structural Propensity Is Repeat Length Dependent.
    Jakubek RS; Workman RJ; White SE; Asher SA
    J Phys Chem B; 2019 May; 123(19):4193-4203. PubMed ID: 31008597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins.
    Masino L; Kelly G; Leonard K; Trottier Y; Pastore A
    FEBS Lett; 2002 Feb; 513(2-3):267-72. PubMed ID: 11904162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.